Collectively, lncRNA CHROMR suppression markedly reduced the phosphorylation levels of HDAC3, enhanced CD20 expression and sensitized DLBCL cells to rituximab, which suggests a promising therapeutic strategy for DLBCL patients with low CD20 expression. This evidence concerns the gene CHROMR and diffuse large B-cell lymphoma.